GALP and obesity due to melanocortin 4 receptor deficiency: Conversely, repeated intranasal administration of GALP continued to decrease food intake and locomotor activity compared with repeated intracerebroventricular injection, suggesting that sensitivity to GALP is maintained and intranasal administration is the best way for GALP to exert its effects against obesity (87).